Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Current Drug Targets|October 28, 2003
Transcription factors as molecular targets: molecular mechanisms of decoy ODN and their designNaruya Tomita, Toshio Ogihara, Ryuichi Morishita
Current Drug Targets|August 17, 2002
HMG-Co A reductase inhibitors in the treatment of cardiovascular diseases: stabilization of coronary artery plaqueRyuichi Morishita, Naruya Tomita, Toshio Ogihara
Expert Review of Cardiovascular Therapy|March 20, 2004
Therapeutic potential of decoy oligonucleotides strategy in cardiovascular diseasesNaruya Tomita, Toshio Ogihara, Ryuichi Morishita
Clinical and Experimental Nephrology|March 27, 2007
Transcription factor decoy oligonucleotide-based therapeutic strategy for renal diseaseNaruya Tomita, Naoki Kashihara, Ryuichi Morishita
Nihon Rinsho. Japanese Journal of Clinical Medicine|May 28, 2002
[Pharmacological effects of HMG-CoA reductase inhibitors]Naruya Tomita, Ryuichi Morishita, Toshio Ogihara
Current Opinion in Pharmacology|April 6, 2004
Molecular therapy to inhibit NFkappaB activation by transcription factor decoy oligonucleotidesRyuichi Morishita, Naruya Tomita, Yasufumi Kaneda, et al.
Current Opinion in Molecular Therapeutics|June 5, 2002
Potential therapeutic applications of decoy oligonucleotidesNaruya Tomita, Ryuichi Morishita, Tetsuya Tomita, et al.
Current Drug Targets|December 8, 2004
Application of decoy oligodeoxynucleotides-based approach to renal diseasesNaruya Tomita, Haruhito Azuma, Yasufumi Kaneda, et al.
Current Drug Targets|April 18, 2003
Gene therapy with transcription factor decoy oligonucleotides as a potential treatment for cardiovascular diseasesNaruya Tomita, Haruhito Azuma, Yasufumi Kaneda, et al.
Pageof 6